Class II transactivator is required for maximal expression of HLA-DOB in B cells

Journal of Immunology

Volumn 168, Issue 4, 2002, Pages 1780-1786

  Nagarajan, Uma M ^a   Lochamy, Jonathan ^a   Chen, Xinjian ^a   Beresford, Guy W ^a   Nilsen, Roger ^a   Jensen, Peter E ^a   Boss, Jeremy M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DO ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TRANSACTIVATOR PROTEIN;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ARTICLE; B LYMPHOCYTE; CONTROLLED STUDY; DNA MICROARRAY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0037083488     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.168.4.1780     Document Type: Article

References (51)

1. MHC class II restricted antigen presentation
2. The HLA-DNA (DZA) gene is correctly expressed as a 1.1 kb mature mRNA transcript
3. The human HLA class II α chain gene DZα is distinct from genes in the DP, DQ and DR subregions
4. DOβ: A new β chain gene in HLA-D with a distinct regulation of expression
5. The α chain gene of H-2O has an unexpected location in the major histocompatibility complex
6. Multiple mechanisms regulate the expression of murine immune response genes
7. A novel class II MHC molecule with unusual tissue distribution
8. Two subsets of epithelial cells in the thymic medulla
9. HLA-DO is a lysosomal resident which requires HLA-DM for efficient intracellular transport
10. HLA-DO is an intracellular class II molecule with distinctive thymic expression
11. Antigen processing: HLA-DO-a hitchhiking inhibitor of HLA-DM
12. Negative regulation by HLA-DO of MHC class II-restricted antigen processing
13. HLA-DO is a negative modulator of HLA-DM-mediated MHC class II peptide loading
14. Altered antigen presentation in mice lacking H2-O
15. Modulation of the major histocompatibility complex class II-associated peptide repertoire by human histocompatibility leukocyte antigen (HLA)-DO
16. A role for HLA-DO as a co-chaperone of HLA-DM in peptide loading of MHC class II molecules
17. Regulation of transcription of MHC class II genes
18. A novel DNA-binding regulatory factor is mutated in primary MHC class II deficiency (bare lymphocyte syndrome)
19. RFXAP, a novel subunit of the RFX DNA binding complex, is mutated in MHC class II deficiency
20. RFX-B is the gene responsible for the most common cause of the bare lymphocyte syndrome, a MHC class II immunodeficiency
21. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients
22. Congenital immunodeficiency with a regulatory defect in MHC class II gene expression lacks a specific HLA-DR promoter binding protein, RF-X
23. Formation of a regulatory factor X/X2 box-binding protein/nuclear factor-Y multiprotein complex on the conserved regulatory regions of HLA class II genes
24. CREB regulates MHC class II expression in a CIITA-dependent manner
25. Function of major histocompatibility complex class II promoters requires cooperative binding between factors RFX and NF-Y
26. Complementation cloning of an MHC class II transactivator mutated in hereditary MHC class II deficiency (or bare lymphocyte syndrome)
27. CIITA coordinates multiple histone acetylation modifications at the HLA-DRA promoter
28. CIITA is a transcriptional coactivator that is recruited to MHC class II promoters by multiple synergistic interactions with an enhanceosome complex
29. Regulation of MHC class II expression by interferon-γ mediated by the transactivator gene CIITA
30. HLA-DMA and HLA-DMB gene expression functions through the conserved S-X-Y region
31. The DMB promoter: Delineation, in vivo footprint, transactivation, and transdominant suppression
32. The bare lymphocyte syndrome: Molecular clues to the transcriptional regulation of major histocompatibility complex class II genes
33. Identification of class II transcriptional activator-induced genes by representational difference analysis: Discoordinate regulation of the DNα/DOβ heterodimer
34. Morphological and virological investigations on cultured Burkitt tumor lymphoblasts (strain Raji)
35. Human B cell variants immunoselected against a single Ia antigen subset have lost expression of several Ia antigen subsets
36. Characterization of the expressed CIITA allele in the class II MHC transcriptional mutant RJ2.2.5
37. Isolation of cytoplasmic RNA from mammalian cells
38. Affymetrix gene chip
39. MHC class II gene silencing in trophoblast cells is caused by inhibition of CIITA expression
40. Mutational analysis of the MHC class II transactivator (CIITA) indicates a functional requirement for conserved LCD motifs and for interactions with the conserved W-box promoter element
41. 2-microglobulin genes
42. Class II MHC transcriptional mutants are defective in higher order complex formation
43. Preparation of cells and reagents for flow cytometry
44. Mapping cis-acting defects in promoters of transcriptionally silent DQA2 DQB2, and DOB genes
45. Transcriptional regulation of major histocompatibility complex class II genes
46. Formaldehyde cross-linking and immunoprecipitation demonstrate developmental changes in H1 association with transcriptionally active genes
47. A simplified formaldehyde fixation and immunoprecipitation technique for studying protein-DNA interactions
48. Mice lacking the MHC class II transactivator (CIITA) show tissue-specific impairment of MHC class II expression
49. Regulation of MHC class I and II gene transcription: Differences and similarities
50. Site a is crucial for two routes of IFNγ-induced MHC class I transactivation: The ISRE-mediate route and a novel pathway involving CIITA
51. What to do with HLA-DO?